Joan Frigola
Overview
Explore the profile of Joan Frigola including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
175
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bernatowicz K, Amat R, Prior O, Frigola J, Ligero M, Grussu F, et al.
J Immunother Cancer
. 2025 Jan;
13(1.
PMID: 39800381
Background: The efficacy of immune checkpoint inhibitors (ICIs) depends on the tumor immune microenvironment (TIME), with a preference for a T cell-inflamed TIME. However, challenges in tissue-based assessments via biopsies...
2.
Cedres S, Serna G, Gonzalez-Medina A, Valdivia A, Assaf-Pastrana J, Iranzo P, et al.
Cancers (Basel)
. 2023 Jul;
15(14).
PMID: 37509274
MPM is an aggressive disease with an immunosuppressive tumor microenvironment, and interest in exploring immunotherapy in this disease has been increasing. In the first line of treatment, the combination of...
3.
Carbonell C, Frigola J, Pardo N, Callejo A, Iranzo P, Valdivia A, et al.
Mol Oncol
. 2023 Feb;
17(5):779-791.
PMID: 36852704
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis are the main therapeutic option for patients with advanced non-small cell lung cancer (NSCLC) without a druggable oncogenic alteration. Nevertheless, only a...
4.
Serra-Camprubi Q, Verdaguer H, Oliveros W, Lupion-Garcia N, Llop-Guevara A, Molina C, et al.
Clin Cancer Res
. 2022 Nov;
29(2):432-445.
PMID: 36374558
Purpose: Cholangiocarcinoma (CCA) is usually diagnosed at advanced stages, with limited therapeutic options. Preclinical models focused on unresectable metastatic CCA are necessary to develop rational treatments. Pathogenic mutations in IDH1/2,...
5.
Valencia K, Echepare M, Teijeira A, Pasquier A, Bertolo C, Sainz C, et al.
J Exp Med
. 2022 Sep;
219(12).
PMID: 36169652
Lung cancer remains the leading cause of cancer-related death worldwide. We identify DSTYK, a dual serine/threonine and tyrosine non-receptor protein kinase, as a novel actionable target altered in non-small cell...
6.
Iranzo P, Callejo A, Assaf J, Molina G, Lopez D, Garcia-Illescas D, et al.
Front Med (Lausanne)
. 2022 Jun;
9:875974.
PMID: 35707528
In recent years, immunotherapy-based regimens have been included into the treatment's algorithm of several cancer types. Programmed death-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) interact with their ligands found...
7.
Frigola J, Carbonell C, Irazno P, Pardo N, Callejo A, Cedres S, et al.
J Immunother Cancer
. 2022 Apr;
10(4).
PMID: 35477861
Background: Immune checkpoint inhibitors (ICIs) targeting the programmed cell death 1/programmed death-ligand 1 axis have transformed the management of advanced non-small cell lung cancer (NSCLC). However, many patients do not...
8.
Cedres S, Assaf J, Iranzo P, Callejo A, Pardo N, Navarro A, et al.
Sci Rep
. 2021 Nov;
11(1):21357.
PMID: 34725384
CheckMate 743 trial demonstrated survival benefit of immunotherapy in first line in MPM with some differences in the efficacy of chemotherapy according to histology. The objective of this study is...
9.
Colominas L, Castanyer P, Frigola J, Tremoleda J
Animals (Basel)
. 2021 Aug;
11(8).
PMID: 34438672
Some of the deposits of animal remains documented throughout prehistory and history are clearly something other than ordinary waste from meat consumption. For the Roman period and based on their...
10.
Callejo A, Frigola J, Iranzo P, Carbonell C, Diaz N, Marmolejo D, et al.
Cancers (Basel)
. 2021 Jul;
13(13).
PMID: 34209601
Immune checkpoint inhibitors (ICIs) have transformed non-small cell lung cancer (NSCLC) treatment. Unfortunately, only some patients benefit from these therapies. Thus, certain clinicopathological characteristics of the patients have been proposed...